Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo

Leukemia

Volumn 27, Issue 11, 2013, Pages 2262-2264

  Soderquist, R ^a   Bates, D J P ^a   Danilov, A V ^a   Eastman, A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CD40 LIGAND; DASATINIB; FLUDARABINE; GOSSYPOL; ISOSORBIDE; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; EX VIVO STUDY; GENETIC HETEROGENEITY; HUMAN; LETTER; LEUKEMIA CELL; LYMPH NODE; NEUTROPENIA; PRIORITY JOURNAL; STROMA; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT; UPREGULATION;

BIPHENYL COMPOUNDS; CONTRACEPTIVE AGENTS, MALE; DRUG RESISTANCE, NEOPLASM; GOSSYPOL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STROMAL CELLS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84887318592     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.138     Document Type: Letter

References (15)

1. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389. (Pubitemid 28193890)
2. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
3. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
4. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
5. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of Navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
6. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
7. Gé linas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005; 19: 1263-1268. (Pubitemid 41003016)
8. Zhang L, Lopez H, George NM, Liu X, Pang X, Luo X. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ 2011; 18: 864-873.
9. Albershardt TC, Salerni BL, Soderquist RS, Bates DJP, Pletnev AA, Kisselev AF et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem 2011; 286: 24882-24895.
10. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-3176.
11. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011; 117: 156-164.
12. Neron S, Pelletier A, Chevrier M-C, Monier G, Lemieux R, Darveau A. Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand. Immunol Invest 1996; 25: 79-89. (Pubitemid 26081072)
13. Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816.
14. Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-2202.
15. Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 487-498.